Bladder cancer
Conditions
Interventions
None listed
Sponsors
Iwate Medical University Institute for Biomedical Sciences Division of Biomedical Research and Development
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those who have agreed to participate in the research 2) Cases in which TUR-Bt is performed for high-risk bladder cancer (multiple, recurrence, T1 or higher, high grade, including CIS, etc.), or within 2 years after the operation 3) Histological diagnosis of urothelial cancer 4) Expected life expectancy is 6 months or more 5) With or without additional postoperative therapy (2nd TUR-Bt, BCG therapy, chemotherapy, total cystectomy) 6) Regardless of recurrence / regrowth and treatment status at the start of blood collection 7) Regardless of age, gender, performance states, etc.
Exclusion criteria
Exclusion criteria: 1) Patients who have difficulty in outpatient visits 2) Patients with psychiatric symptoms who have difficulty participating in the study 3) Patients with serious complications 4) Patients judged by the principal investigator to be inappropriate for registration 5) Cases in which pathological diagnosis and sequence analysis cannot be compatible due to the small amount of tumor sample
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic lead time(day precedes relapse diagnosis by imaging modalities) | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease of plasma and urinary pellet VAF or disappearance of mutant alleles in recurrence-free cases | — |
Countries
Japan
Contacts
Public ContactMasakazu Abe
Iwate Medical University Institute for Biomedical Sciences Division of Biomedical Research and Development
Outcome results
None listed